spacer
The Healthcare Sales & Marketing Network celebrates 26 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  isavuconazole 

 HSMN NewsFeed - 11 Mar 2024
FDA Grants Orphan Drug and Pediatric Exclusivities for CRESEMBA(R) (isavuconazonium sulfate) for Invasive Aspergillosis and Invasive Mucormycosis in Children
Biopharmaceuticals FDA
 HSMN NewsFeed - 14 Jun 2019
SCYNEXIS Appoints Dr. Nkechi Azie as Vice President of Clinical Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 May 2010
Basilea's Toctino(R) receives marketing authorization in Italy
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 18 Nov 2009
Basilea's Toctino(R) receives marketing authorization in Canada
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 14 Oct 2009
Basilea's Toctino(R) receives marketing authorization in Switzerland
Biopharmaceuticals Dermatology Regulatory
 HSMN NewsFeed - 5 May 2009
Basilea's Toctino(R) receives marketing authorization in Spain
Biopharmaceuticals Dermatology Regulatory
 HSMN NewsFeed - 29 Apr 2009
Basilea's Toctino(R) Receives Marketing Authorization in Netherlands
Biopharmaceuticals Dermatology Regulatory
 HSMN NewsFeed - 17 Mar 2009
Basilea's Toctino(R) receives marketing authorization in Austria
Biopharmaceuticals Dermatology Regulatory
 HSMN NewsFeed - 11 Mar 2009
Basilea's Toctino(R) Receives Marketing Authorization in Belgium and Luxemburg
Biopharmaceuticals Dermatology Regulatory
 HSMN NewsFeed - 24 Feb 2009
Basilea Pharmaceutica files claims against Johnson&Johnson over its handling of ceftobiprole (ZEFTERA(TM)/Zevtera(TM)) clinical studies
Biopharmaceuticals Litigation
 HSMN NewsFeed - 17 Dec 2008
Basilea Pharmaceutica opens U.S. phase III study on alitretinoin for the treatment of severe chronic hand eczema
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 21 Nov 2008
Zevtera(TM) (ceftobiprole medocaril), the novel anti-MRSA broad-spectrum antibiotic, receives a positive opinion from the CHMP
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 21 Oct 2008
Basilea's Toctino(R) (alitretinoin) receives marketing authorization in France
Biopharmaceuticals Regulatory Dermatology
 HSMN NewsFeed - 15 Oct 2008
Basilea's Toctino(R) (alitretinoin) receives marketing authorization in Finland
Biopharmaceuticals Dermatology Regulatory
 HSMN NewsFeed - 22 Sep 2008
Basilea's Toctino(R) (alitretinoin) receives marketing authorization in Denmark
Biopharmaceuticals Dermatology Regulatory
 HSMN NewsFeed - 8 Sep 2008
Basilea's Toctino(R) (alitretinoin) receives first national marketing authorization in the UK
Biopharmaceuticals Dermatology Regulatory
 HSMN NewsFeed - 30 Jun 2008
Ceftobiprole, a new anti-MRSA broad-spectrum antibiotic, receives its first marketing authorization by Health Canada
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 19 Feb 2007
Basilea Reports Positive Phase III Results for Alitretinoin
Biopharmaceuticals
 HSMN NewsFeed - 19 Dec 2006
Basilea Announces Start of Phase III Program for Isavuconazole, Its Third Investigational Drug to Reach Pivotal Trials
Biopharmaceuticals
 HSMN NewsFeed - 7 Dec 2006
Basilea to Co-Promote Ceftobiprole
Biopharmaceuticals
Return to NewsFeed  
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.